Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,036 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06542159RecruitingPhase 2
Adaptive radiation for early-stage lung cancer or small metastases
This trial tests a more precise radiation technique (stereotactic body radiotherapy) for early-stage lung cancer or small lung tumors. It aims to reduce side effects by eliminating the usual safety margin around the tumor.
Guangzhou, GuangdongAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06692972Recruiting
How lung cancer tumors change after high-dose radiation
This study looks at how the main lung tumor shrinks or changes after a complete course of high-dose radiation in people with stage II or III lung cancer. It uses scans taken before and after treatment to track the results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06712745RecruitingEarly Phase 1
Personalized lung cancer radiation therapy study
This trial tests a new approach to radiation therapy for central lung cancers, giving high doses in very short bursts to see if it's safe and effective. It may be an option for people whose tumors are not too large and are in a specific central location.
Dallas, TexasAges 18 years+ - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06790797Recruiting
Predicting immunotherapy success in chest cancers
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
Suzhou, JiangsuAges 18–80 - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Oxnard, CaliforniaAges 18 years+ - NCT06902272RecruitingPhase 2
Blood test to predict chemo-immunotherapy response in lung cancer
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Miami, FloridaAges 18 years+ - NCT07027514RecruitingPhase 1
Study of Tolododekin Alfa with immunotherapy for advanced lung cancer
This trial tests a new drug, Tolododekin Alfa, combined with an immunotherapy drug for advanced non-small cell lung cancer. It aims to see if this combination can help shrink tumors and improve outcomes.
Indianapolis, IndianaAges 18 years+ - NCT07133425RecruitingPhase 2
Study of a new immune drug for resistant lung cancer
This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.
Houston, TexasAges 18 years+ - NCT07174388Recruiting
Study comparing treatments for advanced lung cancer using medical records
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
Monterey, CaliforniaAges 18 years+ - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07677787Recruiting
PET/CT imaging for small cell lung cancer
This trial uses a special PET/CT scan to look for a protein called DLL3 in small cell lung cancer. The scan may help doctors better see and understand the cancer. You may be able to join if you have suspected or confirmed small cell lung cancer and certain blood markers are high.
Xiamen, FujianAges 18–80 - NCT00682032Recruiting
Beta-glucan for non-small cell lung cancer
This study tests whether beta-glucan, a supplement taken by mouth, can help people with non-small cell lung cancer. You may be able to join if you’re newly diagnosed (no recent treatment) and can safely take pills.
Louisville, KentuckyAges 18 years+ - NCT00301119Recruiting
Lung cancer screening using risk factors and test results
This study looks at how to find lung cancer earlier by screening people based on their lung-cancer risk. It may help doctors decide who needs further testing if lung nodules are found.
New York, New YorkAges 50 years+ - NCT07477158Recruiting
Comparing two lung cancer surgeries for recovery and quality of life
This study compares two types of lung cancer surgery—removing just the tumor section (segmentectomy) or the whole lobe (lobectomy)—done through small cuts (minimally invasive). The goal is to see which approach leads to better daily living and recovery for early-stage lung cancer patients.
Madrid, MadridAges 18 years+ - NCT07480213RecruitingPhase 1/Phase 2
CAR-NK cell therapy for relapsed small cell lung cancer
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07489391Recruiting
Exercise during radiation for lung cancer
This trial tests whether adding a structured exercise program during radiation and chemotherapy helps people with locally advanced lung cancer. It aims to improve physical function and quality of life.
Barcelona, CataloniaAges 18 years+ - NCT07513818Recruiting
Low-dose CT screening for lung cancer in France
This study tests whether regular low-dose CT scans (a type of X-ray) can find lung cancer early in current or former smokers. Early detection may help catch cancer when it's easier to treat.
Lyon, FranceAges 50–74 - NCT07535463RecruitingPhase 1/Phase 2
Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Basking Ridge, New JerseyAges 18 years+ - NCT07565987Recruiting
Stereotactic Radiation for Advanced Lung Cancer Without Chemotherapy
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
Jhajjar, HaryanaAges 18–75
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,036 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.